Biological ageing and healthspan endpoints — compounds assessed
The 9 compounds the Institute assesses in biological ageing and healthspan endpoints.
§4Compounds assessed
Compounds the Institute assesses in this indication, with the class of each and its overall certainty. A compound appears here whether or not the evidence supports its use, because recording that a compound has been studied and found wanting is as much part of the assessment as recording that one has not.
-
No human trial identified — —
Very low -
Growth-hormone-releasing hormone analogue with albumin-binding drug affinity complex0 contributing trialsfull monograph
No randomised human evidence identified — No trial supports any ageing or healthspan claim.
Very low -
Russian observational and small controlled reports describe mortality and functional differences over multi-year follow-up — The Institute assesses these reports as not permitting a certainty rating above very low. It records that mortality claims of this…
Very low -
No randomised human evidence for any systemic ageing endpoint — The declining-with-age plasma concentration is an observation, not evidence of an intervention effect.
Very low -
No randomised evidence for any ageing endpoint — —
Very low -
No randomised controlled human trial identified — Observational associations between endogenous MOTS-c concentration and metabolic phenotype exist; these are associations, not intervention evidence.
Very low -
No randomised controlled human trial of administered NAD+ on any ageing endpoint identified — Trials of the oral precursors nicotinamide riboside and nicotinamide mononucleotide exist and report raised blood NAD+ concentrations with limited functional effect…
Very low -
No randomised human evidence identified — Marketing claims in this indication are not supported by any trial the Institute has been able to locate.
Very low -
No assessable evidence identified — —
Very low
References cited on this page
References are numbered in order of first citation in this document. Each superscript in the text links to its entry below.
- Lee C, Zeng J, Drew BG, Sallam T, Martin-Montalvo A, Wan J, Kim SJ, Mehta H, Hevener AL, de Cabo R, Cohen P. The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance. Cell Metabolism 2015;21(3):443–454. doi:10.1016/j.cmet.2015.02.009 · PMID 25738459
Identifiers are reproduced only where the Institute holds them. Where a digital object identifier or PubMed identifier is not shown, the Institute has recorded the journal and year and has not constructed an identifier.